AR069386A1 - Formulaciones de emulsion de derivados de pirazolona y kits - Google Patents
Formulaciones de emulsion de derivados de pirazolona y kitsInfo
- Publication number
- AR069386A1 AR069386A1 ARP080105053A ARP080105053A AR069386A1 AR 069386 A1 AR069386 A1 AR 069386A1 AR P080105053 A ARP080105053 A AR P080105053A AR P080105053 A ARP080105053 A AR P080105053A AR 069386 A1 AR069386 A1 AR 069386A1
- Authority
- AR
- Argentina
- Prior art keywords
- emulsion
- formulation according
- active
- emulsion formulation
- pyrazolone derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Las formulaciones de emulsion Incluyen un agente activo de derivado de pirazolona por ejemplo, Edaravona, aceite, agua y-un emulsionante. También se proporcionan métodos de elaboracion y utilizacion de las formulaciones de emulsion en cuestion. Reivindicacion 1: Una formulacion de emulsion que comprende: un agente activo de derivado de pirazolona; aceite; agua; y un emulsionante. Reivindicacion 3: La formulacion de emulsion de acuerdo con la reivindicacion 1, en donde dicha formulacion se encuentra libre de alcohol. Reivindicacion 4: La formulacion de emulsion de acuerdo con la reivindicacion 1, en donde dicha formulacion se encuentra libre de reductor. Reivindicacion 5: La formulacion de emulsion de acuerdo con la reivindicacion 1, en donde dicha formulacion se encuentra libre de quelador. Reivindicacion 6: La formulacion de emulsion de acuerdo con la reivindicacion 1, en donde dicho agente activo de derivado de pirazolona se encuentra presente en una cantidad en el rango de 1,0 a 30 mg/ml. Reivindicacion 8: La formulacion de emulsion de acuerdo con la reivindicacion 1, en donde dicho emulsionante se selecciona de fosfolípido de yema de huevo o fosfolípido de soja. Reivindicacion 10: La formulacion de emulsion de acuerdo con la reivindicacion 1, en donde dicho agente activo de derivado de pirazolona es Edaravona o una sal de la misma o hidrato de la misma fisiologicamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98970707P | 2007-11-21 | 2007-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069386A1 true AR069386A1 (es) | 2010-01-20 |
Family
ID=40642635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105053A AR069386A1 (es) | 2007-11-21 | 2008-11-20 | Formulaciones de emulsion de derivados de pirazolona y kits |
Country Status (13)
Country | Link |
---|---|
US (1) | US8168670B2 (es) |
EP (1) | EP2230912A4 (es) |
JP (1) | JP5509090B2 (es) |
KR (2) | KR101235085B1 (es) |
CN (1) | CN101801195A (es) |
AR (1) | AR069386A1 (es) |
AU (1) | AU2008326593B2 (es) |
BR (1) | BRPI0815597A2 (es) |
CA (1) | CA2695605C (es) |
EA (1) | EA018458B1 (es) |
TW (1) | TWI376240B (es) |
WO (1) | WO2009067343A1 (es) |
ZA (1) | ZA201000780B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101966149B (zh) * | 2010-09-25 | 2012-02-15 | 西安力邦制药有限公司 | 一种脑梗塞治疗药物脂肪乳剂的制备 |
US8747534B2 (en) * | 2010-12-29 | 2014-06-10 | United States Gypsum Company | Antimicrobial size emulsion and gypsum panel made therewith |
CN102058531B (zh) * | 2011-01-11 | 2012-09-19 | 西安力邦制药有限公司 | 一种脑保护治疗药物脂肪乳剂的制备 |
CN109125261B (zh) * | 2016-03-16 | 2021-11-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
EP3785703A1 (en) * | 2017-01-17 | 2021-03-03 | Treeway TW001 B.V. | Treatment comprising oral or gastric administration of edaravone |
CN109431966B (zh) * | 2018-04-27 | 2020-09-22 | 首都医科大学附属北京天坛医院 | 依达拉奉药物组合物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4185100A (en) * | 1976-05-13 | 1980-01-22 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
JPS5931689B2 (ja) * | 1978-01-23 | 1984-08-03 | 富士写真フイルム株式会社 | 油溶性写真用添加剤の分散方法 |
US4360518A (en) * | 1979-08-06 | 1982-11-23 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
DE3308881A1 (de) * | 1983-03-12 | 1984-09-13 | Bayer Ag, 5090 Leverkusen | Verwendung von pyrazolonderivaten als lipoxygenasehemmer, bei der therapie von ischaemien und herzrhythmusstoerungen sowie von rheumatischen, allergischen und asthmatischen erkrankungen, oedemen, lungenembolien, pulmonaler hypertension, sauerstoffintoxikation und ulcerationen, arzneimittel hierfuer und verfahren zu deren herstellung |
DE3312581A1 (de) * | 1983-04-08 | 1984-10-11 | Bayer Ag, 5090 Leverkusen | Verwendung von pyrazolonderivaten bei der bekaempfung des wachstums von tumorzellen und der metastasenbildung, arzneimittel hierfuer und verfahren zu deren herstellung |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
ATE428470T1 (de) * | 2000-06-29 | 2009-05-15 | Mei Co Ltd | Heilmittel zur behandlung von erkrankungen des sehnervs |
KR100921199B1 (ko) * | 2001-05-11 | 2009-10-13 | 미쓰비시 타나베 파마 코퍼레이션 | 안정하고 고농도인 피라졸론 유도체를 포함하는 주사제 |
KR20050114606A (ko) * | 2003-01-10 | 2005-12-06 | 미츠비시 웰파마 가부시키가이샤 | 혈액뇌관문 파탄 억제제 |
CN1440749A (zh) * | 2003-03-24 | 2003-09-10 | 南昌弘益科技有限公司 | 易达拉封注射剂及其制备工艺——治疗急性脑梗塞 |
DE102004025357B4 (de) | 2004-05-19 | 2007-03-29 | Beiersdorf Ag | Emulsionskonzentrat mit wasserlöslichen und öllöslichen Polymeren und kosmetische Zubereitung enthaltend Emulsionskonzentrat sowie ein Verfahren zu dessen Herstellung und dessen Verwendung |
JP4746856B2 (ja) * | 2004-08-12 | 2011-08-10 | 三笠製薬株式会社 | ピラゾロン系製剤 |
US20070116769A1 (en) * | 2004-11-01 | 2007-05-24 | Novozymes A/S | Continuous encapsulation process |
US20060189682A1 (en) | 2005-02-02 | 2006-08-24 | Payne Joseph E | Water soluble prodrugs of COX-2 inhibitors |
JP2006298774A (ja) * | 2005-04-15 | 2006-11-02 | Lead Chemical Co Ltd | 経皮吸収型フリーラジカル抑制製剤 |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
-
2008
- 2008-11-07 JP JP2010535000A patent/JP5509090B2/ja not_active Expired - Fee Related
- 2008-11-07 BR BRPI0815597-6A2A patent/BRPI0815597A2/pt not_active IP Right Cessation
- 2008-11-07 CN CN200880104981A patent/CN101801195A/zh active Pending
- 2008-11-07 US US12/267,304 patent/US8168670B2/en not_active Expired - Fee Related
- 2008-11-07 KR KR1020107003798A patent/KR101235085B1/ko not_active IP Right Cessation
- 2008-11-07 WO PCT/US2008/082842 patent/WO2009067343A1/en active Application Filing
- 2008-11-07 KR KR1020127027858A patent/KR20120125403A/ko not_active Application Discontinuation
- 2008-11-07 AU AU2008326593A patent/AU2008326593B2/en not_active Ceased
- 2008-11-07 EP EP08852188.5A patent/EP2230912A4/en not_active Withdrawn
- 2008-11-07 CA CA2695605A patent/CA2695605C/en not_active Expired - Fee Related
- 2008-11-07 EA EA201000266A patent/EA018458B1/ru not_active IP Right Cessation
- 2008-11-20 AR ARP080105053A patent/AR069386A1/es not_active Application Discontinuation
- 2008-11-20 TW TW097144785A patent/TWI376240B/zh active
-
2010
- 2010-02-02 ZA ZA2010/00780A patent/ZA201000780B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009067343A1 (en) | 2009-05-28 |
EP2230912A4 (en) | 2013-05-01 |
CN101801195A (zh) | 2010-08-11 |
US20090131496A1 (en) | 2009-05-21 |
AU2008326593B2 (en) | 2013-09-05 |
TW200936181A (en) | 2009-09-01 |
CA2695605A1 (en) | 2009-05-28 |
TWI376240B (en) | 2012-11-11 |
EA201000266A1 (ru) | 2010-10-29 |
KR101235085B1 (ko) | 2013-02-20 |
JP2011504177A (ja) | 2011-02-03 |
EP2230912A1 (en) | 2010-09-29 |
CA2695605C (en) | 2013-04-09 |
US8168670B2 (en) | 2012-05-01 |
JP5509090B2 (ja) | 2014-06-04 |
ZA201000780B (en) | 2011-04-28 |
AU2008326593A1 (en) | 2009-05-28 |
BRPI0815597A2 (pt) | 2014-09-30 |
KR20120125403A (ko) | 2012-11-14 |
KR20100091939A (ko) | 2010-08-19 |
EA018458B1 (ru) | 2013-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069386A1 (es) | Formulaciones de emulsion de derivados de pirazolona y kits | |
AR056808A1 (es) | Formulacion de aceite en agua de avermectinas | |
NZ610465A (en) | Clevidipine emulsion formulations containing antimicrobial agents | |
Bowman et al. | Tick salivary glands: function, physiology and future | |
CL2017002488A1 (es) | Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012) | |
AR086467A1 (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
BR112015012840A2 (pt) | composto, composição, e, uso de um composto ou um sal, solvato, éster ou pró-droga farmaceuticamente aceitável do mesmo | |
BRPI0509708B8 (pt) | espuma farmacêutica, composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbídeo e/ou triglicerídeos de cadeia média e uso | |
PE20130217A1 (es) | Composiciones farmaceuticas y metodos para su elaboracion | |
CL2007002228A1 (es) | Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado. | |
AR061289A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
CL2011002053A1 (es) | Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel. | |
ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
NZ603176A (en) | Low-oil pharmaceutical emulsion compositions comprising progestogen | |
PA8656401A1 (es) | 3-amino-pirazol1(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento | |
ES2570599T3 (es) | Composición suave para desinfección cutánea | |
AR071123A1 (es) | Composiciones para duchas y banos de inmersion | |
CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
CN101039689A (zh) | 用于上皮相关病症的局部组合物和方法 | |
BRPI0913326C1 (pt) | formulação farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
BR112012015016A8 (pt) | Formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação | |
RU2008105323A (ru) | Консервирующая композиция для офтальмологического применения | |
BRPI0416650A (pt) | composição de lipossoma estável para a aplicação de um agente farmacêutico, composição de lipossoma estéril e estável para a aplicação de um agente farmacêutico método para a produção de uma composição de lipossoma estável para a aplicação de um agente farmacêutico, composição farmacêutica, uso de uma composição de lipossoma, dispositivo para conter uma composição de lipossoma estável, kit para a aplicação de um agente farmacêutico a um paciente, método para aumentar a estabilidade de composições de lipossomas, método para a identificação de uma composição de lipossoma estável na fase, composição de lipossoma e composição de lipossoma estável na fase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |